Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis

LLufriu, S. (Sara); Sepulveda, M. (María); Blanco, Y. (Yolanda); Marin, P. (Pedro); Moreno, B. (Beatriz); Berenguer, J. (Joan); Gabilondo, I. (Íñigo); Martinez-Heras, E. (Eloy); Sola-Valls, N. (Nuria); Arnaiz, J.A. (Joan Albert); Andreu, E.J. (Enrique José); Fernandez, B. (Begoña); Bullich, S. (Santi); Sanchez-Dalmau, B. (Bernardo); Graus, F. (Francesc); Villoslada, P. (Pablo); Saiz, A. (Albert)

Keywords:

Inflamatory MRI
Mesenchymal stem cells
Autologous

Issue Date:

2014

Publisher:

Public Library of Science

ISSN:

1932-6203

Citation:

Llufriu S, Sepúlveda M, Blanco Y, Marín P, Moreno B, Berenguer J, et al. Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis. PLoS One. 2014 Dec 1;9(12):e113936.

Abstract

Bone-marrow-MSCs are safe and may reduce inflammatory MRI parameters supporting their immunomodulatory properties. ClinicalTrials.gov NCT01228266.

URI:

https://hdl.handle.net/10171/38250

DOI:

http://dx.doi.org/10.1371/journal.pone.0113936

Appears in Collections:

DA - CUN - Área de Terapia Celular - Artículos de revista

Files in This Item:

File

pone.0113936.pdf

Description

Size

655.82 kB

Format

Adobe PDF

View/Open

Statistics and impact

Statistics

0 citas en

125 citas en

Google Scholar

Show full item record